当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
Phenylephrine Hydrochloride 100mcg/mL (1mg/10mL)
HUMAN COMPOUNDED DRUG
69374-957
Nephron Sterile Compounding Center, LLC
2024-2
PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
100 ug/1 mL
69374-957-10
Amino Acid 50gm/1000ml
HUMAN COMPOUNDED DRUG
69374-988
Nephron Sterile Compounding Center, LLC
2024-2
LYSINE HYDROCHLORIDE; ARGININE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5000 g/1 mL; 5000 g/1 mL
69374-988-10
Labetalol Hydrochloride Injection 5 mg/mL
HUMAN COMPOUNDED DRUG
69374-946
Nephron Sterile Compounding Center, LLC
2024-2
LABETALOL HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL
69374-946-34
Fentanyl Citrate in 0.9% Sodium Chloride Injection
HUMAN COMPOUNDED DRUG
69374-323
Nephron Sterile Compounding Center, LLC
2024-2
FENTANYL CITRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.5 mg/250 mL
69374-323-25
Ampotericin/ Chloramphenicol/ HC
HUMAN COMPOUNDED DRUG
26436-5483
Hybrid Pharma
2024-2
HYDROCORTISONE; AMPHOTERICIN B; CHLORAMPHENICOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 g; 50 mg/1 g; 500 mg/1 g
26436-5483-2
Ampotericin/ Chloramphenicol/ HC
HUMAN COMPOUNDED DRUG
26436-5483
Hybrid Pharma
2024-2
HYDROCORTISONE; AMPHOTERICIN B; CHLORAMPHENICOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 g; 50 mg/1 g; 500 mg/1 g
26436-5483-1
Progesterone 125mg
HUMAN COMPOUNDED DRUG
26436-5248
Hybrid Pharma
2024-2
PROGESTERONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
125 mg
26436-5248-1
Naltrexone 2mg
HUMAN COMPOUNDED DRUG
26436-0724
Hybrid Pharma
2024-2
NALTREXONE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg
26436-0724-9
Ampotericin/ Iodochlorohydroxyquin 5/3
HUMAN COMPOUNDED DRUG
26436-5484
Hybrid Pharma
2024-2
AMPHOTERICIN B; CLIOQUINOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
50 mg/1 g; 30 mg/1 g
26436-5484-2
Taurine 50mg/mL
HUMAN COMPOUNDED DRUG
26436-5024
Hybrid Pharma
2024-2
TAURINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
50 mg/1 mL
26436-5024-3
DMSO 50%
HUMAN COMPOUNDED DRUG
26436-5091
Hybrid Pharma
2024-2
DIMETHYL SULFOXIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
30 [PNU]/1 mL
26436-5091-5
Sodium Citrate and Gentamicin Solution
HUMAN COMPOUNDED DRUG
71266-6670
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
TRISODIUM CITRATE DIHYDRATE; GENTAMICIN SULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
40 mg/1 mL; .32 mg/1 mL
71266-6670-1
Sodium Citrate and Gentamicin Solution
HUMAN COMPOUNDED DRUG
71266-6670
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
TRISODIUM CITRATE DIHYDRATE; GENTAMICIN SULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
40 mg/1 mL; .32 mg/1 mL
71266-6670-4
Sodium Citrate and Gentamicin Solution
HUMAN COMPOUNDED DRUG
71266-6670
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
TRISODIUM CITRATE DIHYDRATE; GENTAMICIN SULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
40 mg/1 mL; .32 mg/1 mL
71266-6670-3
Lidocaine HCl 2%
HUMAN COMPOUNDED DRUG
71266-9090
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
LIDOCAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 mg/1 mL
71266-9090-1
Lidocaine HCl 2%
HUMAN COMPOUNDED DRUG
71266-9090
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
LIDOCAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 mg/1 mL
71266-9090-9
Atropine Sulfate
HUMAN COMPOUNDED DRUG
71266-2010
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories
2024-2
ATROPINE SULFATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.4 mg/1 mL
71266-2010-1
031083 FINASTERIDE 0.1% / MINOXIDIL 7%
HUMAN COMPOUNDED DRUG
72934-4352
SKNV
2024-2
FINASTERIDE; MINOXIDIL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.1 g/100 mL; 7 g/100 mL
72934-4352-8
351034 CICLOPIROX 0.77% / CLOBETASOL PROPIONATE 0.05%
HUMAN COMPOUNDED DRUG
72934-7423
SKNV
2024-2
CICLOPIROX OLAMINE; CLOBETASOL PROPIONATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.77 g/100 mL; .05 g/100 mL
72934-7423-6
021030 IMIQUIMOD 5% / SALICYLIC ACID 30% / TRETINOIN 0.1% Gel
HUMAN COMPOUNDED DRUG
72934-1342
SKNV
2024-2
TRETINOIN; SALICYLIC ACID; IMIQUIMOD
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.1 g/100 mL; 30 g/100 mL; 5 g/100 mL
72934-1342-2
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3